Introduction: Alcohol Use Disorders (AUD) is a leading cause of mortality and morbidity worldwide. At present disulfiram, naltrexone and acamprosate are approved for the treatment of AUD in U.S. and Europe. Nalmefene is approved in Europe and sodium oxybate is approved in Italy and Austria only. Baclofen received a â temporary recommendation for useâ in France. Areas covered: The safety of the above mentioned medications on liver, digestive system, kidney function, nervous system, pregnancy and lactation and their possible side effects are described and discussed. Expert opinion: Mechanism of action and metabolism of these drugs as well as patientsâ clinical characteristics can affect the safety of treatment. All approved medications are valid tools for the treatment of AUD in patients without advanced liver disease. For some drugs, attention should be paid to patients with renal failure and medications may be used with caution, adjusting the dosage according to kidney function. In patients with AUD and advanced liver disease, at present only baclofen has been formally tested in randomized controlled trials showing its safety in this population.
Antonelli, M., Ferrulli, A., Sestito, L., Vassallo, G. A., Tarli, C., Mosoni, C., Rando, M. M., Mirijello, A., Gasbarrini, A., Addolorato, G., Alcohol addiction - the safety of available approved treatment options, <<EXPERT OPINION ON DRUG SAFETY>>, 2018; 17 (2): 169-177. [doi:10.1080/14740338.2018.1404025] [http://hdl.handle.net/10807/112815]
Alcohol addiction - the safety of available approved treatment options
Antonelli, Mariangela;Ferrulli, Anna;Sestito, Luisa;Vassallo, Gabriele Angelo;Tarli, Claudia;Rando, Maria Margherita;Mirijello, Antonio;Gasbarrini, Antonio;Addolorato, Giovanni
2018
Abstract
Introduction: Alcohol Use Disorders (AUD) is a leading cause of mortality and morbidity worldwide. At present disulfiram, naltrexone and acamprosate are approved for the treatment of AUD in U.S. and Europe. Nalmefene is approved in Europe and sodium oxybate is approved in Italy and Austria only. Baclofen received a â temporary recommendation for useâ in France. Areas covered: The safety of the above mentioned medications on liver, digestive system, kidney function, nervous system, pregnancy and lactation and their possible side effects are described and discussed. Expert opinion: Mechanism of action and metabolism of these drugs as well as patientsâ clinical characteristics can affect the safety of treatment. All approved medications are valid tools for the treatment of AUD in patients without advanced liver disease. For some drugs, attention should be paid to patients with renal failure and medications may be used with caution, adjusting the dosage according to kidney function. In patients with AUD and advanced liver disease, at present only baclofen has been formally tested in randomized controlled trials showing its safety in this population.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
